| Dawn-marie Gotkiewicz, | |
|
159 Waterdam Rd, Ste 220, Mc Murray, PA 15317-2576 | |
| (724) 969-6970 | |
| Not Available |
| Full Name | Dawn-marie Gotkiewicz |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 159 Waterdam Rd, Mc Murray, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023011640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD060202L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dawn-marie Gotkiewicz, 11279 Perry Hwy, Ste 450, Wexford, PA 15090-9303 Ph: () - | Dawn-marie Gotkiewicz, 159 Waterdam Rd, Ste 220, Mc Murray, PA 15317-2576 Ph: (724) 969-6970 |
News Archive
Most of us think of DNA mutations as the culprits that cause cancer. Scott Ness, PhD, University of New Mexico Professor of Molecular Genetics and Microbiology and Associate Director at the UNM Cancer Center, thinks there may be another, more elusive culprit. If Dr. Ness is right his research, funded as part of the National Cancer Institute's Provocative Questions Project, might open a whole new arena in which to target anticancer drugs.
A special issue of Deutsches -rzteblatt International contains the first scientific presentation of clinical experience with the novel influenza A virus (H1N1/09) in the German-speaking countries since the start of the pandemic.
Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.
McKesson Pharmacy Systems and Automation (MPS&A) has launched a pilot program to test its Adherence Performance reporting solution.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
› Verified 6 days ago
Christine Yost, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 159 Waterdam Rd, Ste 220, Mc Murray, PA 15317 Phone: 724-969-6970 | |
Robert Charles Heslop Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3515 Washington Rd, Suite 558, Mc Murray, PA 15317 Phone: 724-941-4379 Fax: 724-941-3481 | |
Dr. Marc Alan Yester, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3055 Washington Rd, Suite 102, Mc Murray, PA 15317 Phone: 724-969-5025 Fax: 724-969-5001 | |
Tonja J Dicamillo, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6000 Waterdam Plaza Dr, Suite 280, Mc Murray, PA 15317 Phone: 724-941-8199 Fax: 724-942-6423 | |
Dr. Maya Goldin-perschbacher, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3055 Washington Rd, Suite 102, Mc Murray, PA 15317 Phone: 724-969-5025 | |
Charles E Silverstein, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 159 Waterdam Rd, Ste 220, Mc Murray, PA 15317 Phone: 724-969-6970 Fax: 724-969-6975 |